Bristol-Myers Squibb settles whistleblower lawsuit for $30 million

Bristol-Myers Squibb agreed to pay $30 million to the California Department of Insurance to settle allegations the company engaged in marketing fraud and paid kickbacks to physicians.

Three former Bristol-Myers Squibb sales representatives filed a whistleblower lawsuit alleging the company paid kickbacks to increase the prescriptions of several prescription medications, including clopidogrel (Plavix) and pravastatin (Pravachol). Clopidogrel is a blood thinner, while pravastatin is a statin intended to decrease low-density lipoprotein cholesterol.

Former Bristol-Myers Squibb salespeople Mychal Wilson, Lucius Allen and Eve Allen said the misconduct occurred between 1997 and 2003. The company has denied wrongdoing.

Under the terms of the settlement, Bristol-Myers Squibb did not admit to any liability and continued to deny the allegations.

Wilson first filed a complaint in March 2007. Lucius Allen and Eve Allen joined Wilson’s complaint in July 2010. Lucius Allen played for 10 seasons in the National Basketball Association from 1969 through 1979.

They alleged that Bristol-Myers Squibb provided physicians and their families with cash and gifts, including complimentary box suites at sporting events, enrollment in a Los Angeles Lakers basketball camp, pre-paid gold outings, tickets to Broadway plays and dinners, hotel rooms and concert tickets for large-volume prescribers.

In September 2007, Bristol-Myers Squibb and Apothecon, a wholly owned subsidiary, agreed to a settlement with the U.S. Department of Justice for more than $515 million to resolve civil allegations of illegal drug marketing and pricing practices.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."